Neurovation Labs

Assure Holdings Expands Service Offerings to Address the High Growth EEG Services Market

Retrieved on: 
Tuesday, June 27, 2023

The agreement enables the Company to expand its offerings in the field of neurology to include electroencephalogram (“EEG”) testing.

Key Points: 
  • The agreement enables the Company to expand its offerings in the field of neurology to include electroencephalogram (“EEG”) testing.
  • Under the terms of the agreement, Assure has the exclusive rights to offer Neurovative Diagnostics’ comprehensive suite of EEG services to Assure’s current and future hospitals, healthcare facilities and clinics where it provides services.
  • Services provided by Neurovative Diagnostics will be treated as ‘fee-for-service’ enabling Assure to leverage Neurovative Diagnostics’ technologists, market knowledge and expertise.
  • Assure anticipates the launch of EEG services will occur during the third quarter 2023, leveraging its existing Tele neurology services and requiring minimal working capital needs.

Neurovative Diagnostics Announces Partnership with NeuroX

Retrieved on: 
Tuesday, October 25, 2022

ORLANDO, Fla., Oct. 25, 2022 /PRNewswire/ -- Neurovative Diagnostics, a best-in-class industry leader providing in-home EEG testing and Continuous Monitoring services in acute care settings, announced a partnership with NeuroX, a physician-led, global telemedicine company and leading online clinic for neuro-psychology and neuroscience.

Key Points: 
  • ORLANDO, Fla., Oct. 25, 2022 /PRNewswire/ -- Neurovative Diagnostics, a best-in-class industry leader providing in-home EEG testing and Continuous Monitoring services in acute care settings, announced a partnership with NeuroX, a physician-led, global telemedicine company and leading online clinic for neuro-psychology and neuroscience.
  • Dr. Umar Farooq, NeuroX's Medical Director, notes, "Our partnership with Neurovative is another step towards providing high quality and convenient neurological care and remote patient monitoring to our patients.
  • Our partnership with NeuroX is a great example of our evolving healthcare delivery system working towards being more patient-centric."
  • NeuroX, a project of American TelePhysicians Inc., is thrilled to partner with Neurovative Diagnostics, a world-class EEG company, for its Neurology ecosystem in delivering affordable, convenient, and prompt online brain healthcare services at patients' doorsteps".

Neurovations Awarded 6.9 million-Dollar Grant for Groundbreaking Educational Pain Research Program

Retrieved on: 
Thursday, October 13, 2022

NAPA, Calif., Oct. 13, 2022 /PRNewswire/ -- Dr. Eric Grigsby, Founder and CEO of Neurovations, announced that Neurovations Education is the recipient of a 6.9 million-dollar grant from the Helping to End Addiction Long-term Initiative®, or NIH HEAL Initiative®.

Key Points: 
  • "It is an honor to receive this grant and to dive into the heart and mission of improving pain research across the United States.
  • Neurovations was founded in Napa in 1992 by Dr. Eric Grigsby and is a national leader in clinical research, treatment for chronic pain, molecular diagnostics testing, and education programs focused on pain and neuroscience.
  • The Neurovations research and education divisions are an extension of his mission to contribute to the health and well-being of patients.
  • Neurovations is a national leader in medical device and pharmaceutical innovation, clinical research, and a world-class education program focusing in pain and neuroscience.

Neurovation Labs Announces Issuance of Second U.S. Patent Covering Compositions and Methods for Detecting PTSD Biomarker

Retrieved on: 
Wednesday, September 14, 2022

The patent, entitled "Compositions and Methods to Detect GluA1 in Brain and to Identify the Presence of GluA1-Mediated Post-Traumatic Stress Disorder and Other Neurological Disorders," is directed to novel radiotracer compositions as well as methods for detecting GluA1 and GluA1-containing central nervous system receptors.

Key Points: 
  • The patent, entitled "Compositions and Methods to Detect GluA1 in Brain and to Identify the Presence of GluA1-Mediated Post-Traumatic Stress Disorder and Other Neurological Disorders," is directed to novel radiotracer compositions as well as methods for detecting GluA1 and GluA1-containing central nervous system receptors.
  • "The compounds protected by this patent are part of a series of radiotracers that Neurovation Labs is developing to enable objective diagnosis of brain disorders and to better evaluate the mechanisms underlying PTSD and other brain traumas.
  • This patent is owned solely by Neurovation Labs and is the second issuance from a broader intellectual property portfolio stemming from the company's research and development.
  • Neurovation Labs is a biotechnology company revolutionizing the way psychiatric disorders are diagnosed and treated, with an initial focus on PTSD.

Agios Appoints Brian Goff as Chief Executive Officer

Retrieved on: 
Tuesday, July 12, 2022

CAMBRIDGE, Mass., July 12, 2022 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ: AGIO), a leader in the field of cellular metabolism pioneering therapies for genetically defined diseases, today announced that effective August 8, 2022, Jackie Fouse, Ph.D., will transition to the role of chair of the board of directors and Brian Goff will assume the role of chief executive officer. Mr. Goff will also serve as a member of Agios’ board of directors. Current chairman, David Schenkein, M.D., will remain on the board as a director.

Key Points: 
  • Before joining Alexion, Mr. Goff was chief operating officer and a member of the board of directors of Neurovance.
  • Dr. Fouse joined Agios as a member of the board of directors in 2017 and has served as chief executive officer since 2019.
  • Agios will host a virtual investor webcast today at 4:30 p.m. ETwith Jackie Fouse and Brian Goff to discuss Agios CEO transition.
  • Such forward-looking statements include those regarding the expected benefits of Agios chief executive officer succession plan.

Neurovation Labs Awarded Additional Air Force Phase II Contract Worth $1.25M to Develop Tools to Mitigate PTSD and Other Brain Traumas

Retrieved on: 
Tuesday, June 21, 2022

Two of the most significant issues affecting long-term soldier health are TBI and PTSD, which often occur together.

Key Points: 
  • Two of the most significant issues affecting long-term soldier health are TBI and PTSD, which often occur together.
  • Neurovation Labs is addressing critical shortcomings in brain trauma healthcare by assessing and targeting underlying biomarkers.
  • Neurovation Labs is targeting a localized protein increase in the brain to develop the first diagnostic brain scan and companion medication for the disorder.
  • Neurovation Labs is a biotechnology company revolutionizing the way mental health disorders are diagnosed and treated, focusing on PTSD and other brain traumas.

Neurovation Labs Announces Issuance of U.S. Patent Covering Composition and Methods for Detecting PTSD in Living Subjects

Retrieved on: 
Wednesday, January 19, 2022

The patent, entitled "Compositions and Methods to Detect GluA1 in Brain and to Identify the Presence of GluA1-Mediated PTSD," is directed to novel compositions and methods for diagnosing PTSD as well as treating PTSD following such a diagnosis.

Key Points: 
  • The patent, entitled "Compositions and Methods to Detect GluA1 in Brain and to Identify the Presence of GluA1-Mediated PTSD," is directed to novel compositions and methods for diagnosing PTSD as well as treating PTSD following such a diagnosis.
  • "The compound protected by this patent is from one of a series of classes that Neurovation Labs is developing to enable objective diagnosis of PTSD and to better evaluate the mechanisms underlying PTSD and other mental health disorders.
  • This patent is owned solely by Neurovation Labs and is the first issuance from a broader intellectual property portfolio stemming from the company's research and development.
  • Neurovation Labs is a biotechnology company revolutionizing the way psychiatric disorders are diagnosed and treated, with an initial focus on PTSD.

Amp Human Receives $1.5M Phase II Small Business Innovation Research Contract from US Air Force

Retrieved on: 
Monday, August 24, 2020

PARK CITY, Utah, Aug. 24, 2020 /PRNewswire/ --Amp Human, a Park City-based human performance company has been awarded a $1.5 million Phase II Small Business Innovation Research (SBIR) contract by the United States Air Force through the AFWERX innovation program.

Key Points: 
  • PARK CITY, Utah, Aug. 24, 2020 /PRNewswire/ --Amp Human, a Park City-based human performance company has been awarded a $1.5 million Phase II Small Business Innovation Research (SBIR) contract by the United States Air Force through the AFWERX innovation program.
  • The Phase II contract will allow Amp Human to develop a better understanding of a new use case of their flagship product, PR Lotion.
  • Amp Human is a Park City-based human performance company that provides athletes with solutions to optimize performance.
  • For start-ups and small businesses, AFWERX is working with the Small Business Innovation Research (SBIR) program to increase collaboration between the Private Sector and the United States Air Force.

Neurovation Labs Awarded Air Force SBIR Contract to Accelerate PTSD Diagnostic and Treatment Development

Retrieved on: 
Monday, December 16, 2019

NEW YORK, Dec. 16, 2019 /PRNewswire/ -- Neurovation Labs, Inc. , a biotechnology company developing the first objective diagnostic and companion treatment for Post-Traumatic Stress Disorder (PTSD), has been awarded a U.S. Air Force Small Business Innovation Research (SBIR) Phase I contract through AFWERX and Air Force Research Lab (AFRL) to advance the development of these pivotal technologies.

Key Points: 
  • NEW YORK, Dec. 16, 2019 /PRNewswire/ -- Neurovation Labs, Inc. , a biotechnology company developing the first objective diagnostic and companion treatment for Post-Traumatic Stress Disorder (PTSD), has been awarded a U.S. Air Force Small Business Innovation Research (SBIR) Phase I contract through AFWERX and Air Force Research Lab (AFRL) to advance the development of these pivotal technologies.
  • Neurovation Labs is addressing these shortcomings in PTSD healthcare by developing the first diagnostic brain scan and companion medication for the disorder.
  • "We are thrilled to be working with AFWERX and the U.S. Air Force on the development of our PTSD diagnostic and treatment," stated CEO Dr. Jennifer Perusini.
  • Neurovation Labs is now eligible to pursue a Phase II contract with the Air Force.